Madam Speaker, I want to thank the hon. House leader for the NDP. I am very pleased to work with him again in his role as the critic for health. He is absolutely right. I appreciate that these were not always easy conversations. They were indicative of the conversations we had when we were both House leaders. Finding that common ground, as two different parties, is often difficult.
I think, for people like Amber, we can see what the difference is. The cost consequence for Amber of not being able to have access to the life-changing medication she needs, let us be very direct, could be devastating. It could mean that Amber winds up with a heart attack or stroke. It could mean that she has a limb amputated or that she dies. It certainly means that Amber is less productive, less able to contribute to society and almost definitely going to have an earlier death. The cost of not providing that medication is far superseded by those negative outcomes, not just as a matter of social justice but as a matter of material cost.
Are the Conservatives going to be there for Amber? Are they going to be there for people who need their diabetes medication? Are they going to vote for their constituents who need these medications, or are they going to vote against them?